SLC7A11 and familial pancreatic carcinoma: found that SM inhibited the transcriptional regulation of Transcription factor activating enhancer binding protein 2 alpha (TFAP2A) to OTU domain, ubiquitin aldehyde binding 1 (OTUB1) in human pancreatic cancer cells (PANC‐1 and CFPAC‐1), which in turn inhibited the deubiquitination of SLC7A11 proteins by OTUB1, induced SLC7A11 degradation, activating iron death and inhibiting pancreatic cancer cell progression.